Oncology

Back to articles

Newer antiandrogens are effective for metastatic, hormone-sensitive prostate cancer

KEY POINT

Recent studies published in the New England Journal of Medicine evaluated the effectiveness of two treatment options for patients with metastatic, hormone-sensitive prostate cancer. These studies showed that addition of either apalutamide (Erleada—Janssen) or enzalutamide (Xtandi—Astellas) to standard androgen-deprivation therapy (ADT) improved overall survival (OS) and progression-free survival (PFS).

SOURCES

Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.

Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(1):121–31.

Klotz L. Apalutamide for metastatic, hormone-responsive prostate cancer. N Eng J Med. 2019;381(1):84–6.

Tannock IF. Improving treatment for advanced prostate cancer. N Eng J Med. 2019;381(1):176–7.